MSJ

Our journals are part of the international community of @ECTRIMS @ACTRIMS @PACTRIMS_admin @lactrims_org and @eurims You can read our articles on: Multiple Sclerosis Journal journals.sagepub.com/home/msj MSJ Experimental Translational and Clinical journals.sagepub.com/home/mso

In MOG antibody–associated #MOGAD optic neuritis early corticosteroids predicted visual recovery, but MRI lesion extent prediced retinal atrophy. Study from @FondARothschild ▶️ journals.sagepub.com/doi/abs/10.117…

🔊 Listen to @wz_yeh @NDCNOxford @MonashUni on the effects of smoking and vascular risk factors on relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease #MOGAD. 📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.11…

What do you think? Are neurofilament light chain (NfL) levels ready for routine clinical use in #MultipleSclerosis? 5/🧵

And commentary from @karolinskainst: When interpreted longitudinally, within stablished clinical and MRI measures, NfL can enhance risk stratification, treatment monitoring and detection of #MultipleSclerosis. 🔽 journals.sagepub.com/doi/abs/10.117… 4/🧵

New controversy available ⚖️ Are neurofilament light chain (NfL) levels ready for routine clinical use in #MultipleSclerosis? 1/🧵

Cardiovascular comorbidity burden is associated with greater fatigue in #MultipleSclerosis over time. Study from @HopkinsMedicine ▶️ journals.sagepub.com/doi/full/10.11…

Following cancer diagnosis, the use of #MultipleSclerosis treatments declined sharply, without a strong impact on neurology visits and hospitalizations. A multinational cohort study from @ChloePierret @Inserm @RennesUniv_EN @UBC ▶️ journals.sagepub.com/doi/full/10.11…

🔊 Listen to @Mikael__Cohen @CHUdeNice on the comparisons between radiologically isolated syndrome, early #MultipleSclerosis and controls using a digital neurological examination. 📄And read the full manuscript ▶️ journals.sagepub.com/doi/full/10.11…

🔬 Published in the March 2026 issue of the Multiple Sclerosis Journal, (@MSJ_Research), the case report 𝘔𝘺𝘦𝘭𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘙𝘦𝘵𝘪𝘯𝘢𝘭 𝘕𝘦𝘳𝘷𝘦 𝘍𝘪𝘣𝘳𝘦 𝘓𝘢𝘺𝘦𝘳 offers a rare insight into how the nervous system can repair itself in MS, and what this could mean for measuring recovery in clinical trials. By senior author Dr. Nicholas Cunniffe and contributing authors Dr. Gioia Riboni-Verri, Riddhima Gautam and Dr. Benson Chen. → 📄 𝐂𝐚𝐬𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: bit.ly/4c15tle → 🎙️ 𝐏𝐨𝐝𝐜𝐚𝐬𝐭 𝐞𝐩𝐢𝐬𝐨𝐝𝐞: bit.ly/48LIae7 #MultipleSclerosis #Remyelination #ClinicalTrials #MSResearch #ECTRIMS

Neighborhood deprivation was associated with worsening manual dexterity, walking speed and quality of life in people with #MultipleSclerosis 55 years of age and older. Study from @ClevelandClinic @CLENeurons ▶️ journals.sagepub.com/doi/abs/10.117…

Did you attend the Progress in #MultipleSclerosis Research Conference 2025 from @MS_Australia ? Have a look at the abstracts 🔽 journals.sagepub.com/doi/full/10.11…

Interesting study addressing a key issue we are all concerned about as neuroimmunologists. Balancing the risks of treatment vs disease relapse to optimise patient function and safety.

The Number Needed to Treat provides a framework for contextualizing treatment efficacy against potential harms, and was progressively higher in older participants of #MultipleSclerosis trials. Study from @MScentrum020 @amsterdamumc ▶️ journals.sagepub.com/doi/full/10.11…

Technology will help, may be...

Extending low-dose rituximab after at least 1 year of clinical and radiological stability in relapsing #MultipleSclerosis was not associated with an increased risk of disease activity. Study from @KPSCALnews ▶️ journals.sagepub.com/doi/abs/10.117…

Rescue cyclophosphamide treatment was used in 23 people with #MultipleSclerosis from 2009 to 2024, and was associated with improvement in relapse-associated disability. 🔓MSJ-ETC study from @UBC ▶️ journals.sagepub.com/doi/full/10.11…

#NeuroArtFriday The #beauty of #science. "Top 50 most connected diagnoses in the #MultipleSclerosis (MS; left) and control (right) #comorbidity networks."

In a case–control study on viruses and #MultipleSclerosis run in 2003, one person already had intrathecal synthesis of Epstein-Barr virus antibodies 15 years before clinical onset of #MultipleSclerosis. @MSJ_Research journals.sagepub.com/doi/abs/10.117… 1/🧵 journals.sagepub.com/doi/abs/10.117…